United Therapeutics UTHR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Adcirca | $26.9M+15.0% | $30M+26.1% | $26.9M+3.9% | $24.2M-7.6% | $23.4M-16.4% | |
| Nebulized Tyvaso | $549.1M-9.3% | $585.7M-0.2% | $602.7M+3.7% | $620.1M+14.3% | $605.6M+14.7% | |
| Orenitram | $511.8M+14.0% | $496.9M+14.4% | $483.5M+17.8% | $465.6M+19.6% | $448.8M+18.9% | |
| Remodulin | $515.2M-6.0% | $526.8M-2.1% | $533.3M+2.8% | $535.7M+2.7% | $548.3M+9.4% | |
| Tyvaso DPI | $1.32B+19.1% | $1.29B+25.0% | $1.23B+26.0% | $1.17B+28.8% | $1.11B+32.0% | |
| Unituxin | $222.2M-6.8% | $226.8M-5.0% | $232M+2.9% | $245.2M+13.7% | $238.5M+14.6% | |
| Gross Profit by Product | ||||||
| Adcirca | $15.4M+15.8% | $16.9M+23.4% | $15.4M+3.4% | $14M-6.0% | $13.3M-17.9% | |
| Nebulized Tyvaso | $521.8M-8.8% | $558.5M+1.0% | $574.5M+5.4% | $589.2M+16.4% | $571.9M+16.1% | |
| Orenitram | $484M+14.9% | $468.2M+15.3% | $456M+19.2% | $437.3M+20.3% | $421.3M+19.8% | |
| Remodulin | $463.6M-6.3% | $477.5M-2.7% | $478.7M+1.3% | $480.9M+0.9% | $495M+7.1% | |
| Tyvaso DPI | $1.07B+13.7% | $1.08B+22.2% | $1.04B+24.4% | $991.4M+28.5% | $945.4M+32.8% | |
| Unituxin | $204.9M-7.9% | $209.3M-6.7% | $218.2M+4.8% | $230.2M+15.6% | $222.5M+15.4% | |
| Cost of Sales by Product | ||||||
| Adcirca | $11.5M+13.9% | $13.1M+29.7% | $11.5M+4.5% | $10.2M-9.7% | $10.1M-14.4% | |
| Nebulized Tyvaso | $27.3M-19.0% | $27.2M-20.2% | $28.2M-21.0% | $30.9M-14.4% | $33.7M-4.0% | |
| Orenitram | $27.8M+1.1% | $28.7M+1.1% | $27.5M-1.4% | $28.3M+8.8% | $27.5M+6.6% | |
| Remodulin | $51.6M-3.2% | $49.3M+4.0% | $54.6M+18.2% | $54.8M+22.6% | $53.3M+36.0% | |
| Tyvaso DPI | $245.7M+50.6% | $210.6M+41.9% | $190.3M+35.2% | $174.1M+31.1% | $163.2M+27.3% | |
| Unituxin | $17.3M+8.1% | $17.5M+21.5% | $13.8M-19.8% | $15M-9.1% | $16M+3.9% | |
| Total revenues by Geography | ||||||
| ROW | $138.2M-5.5% | $145.7M+5.8% | $138.5M+1.6% | $145.4M+12.3% | $146.3M+17.7% | |
| U.S. | $3.03B+6.5% | $3.04B+10.9% | $2.99B+14.1% | $2.93B+17.9% | $2.85B+20.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
